Takara Bio USA, Inc., (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., is proud to announce that City of Hope has recently procured a SMARTer ICELL8 Single-Cell System to perform high-level studies involving high-throughput single-cell RNA-seq applications. This automated system provides a proven platform for unbiased isolation, evaluation, and selection of over a thousand single cells for downstream analyses, including next-generation sequencing (NGS), backed by recent citations in the literature.

Single-cell RNA-seq has seen many advancements involving automation processes in recent years. While most of these technologies have focused primarily on increasing the number of cells processed, they have not been able to meet the needs of researchers seeking to generate data from preselected single cells. The SMARTer ICELL8 Single-Cell System is an automation platform that enables this work, capable of processing up to eight different samples in parallel and facilitating the analysis of over a thousand single cells or nuclei, regardless of size or shape.

The SMARTer ICELL8 instrument is part of an incredibly flexible system that enables scientists to conduct innovative research and adapt to a wide range of experimental setups. Recently, Professor Nicholas Navin (University of Texas MD Anderson Cancer Center) examined the benefits of the SMARTer ICELL8 system, publishing his studies in Nature Communications which detail a high-throughput 3 single-nucleus RNA sequencing approach for revealing transcriptional diversity in breast cancer cells. Upon learning of these results, City of Hope became interested in using the system to move forward with their own sensitive, single-cell studies.

"Takara Bio is dedicated to doing good science that has a positive impact on human health. We strive to make products that enable researchers to deepen their understanding of relevant samples. The SMARTer ICELL8 system provides an enhanced ability to process large numbers of single cells with a high level of confidence and control" said Carol Lou, President of Takara Bio USA, Inc. "Were thrilled to be able to offer a platform that enables such precise, delicate work while easing the burden on the researcher."

"Flash frozen clinical samples represent a potentially powerful resource for clinical research," said Andrew Farmer, Vice President of Research and Development at TBUSA. "While the freezing process tends to disrupt cell membranes, nuclear membranes tend to remain intact. A system that can process nuclei samples, while also excluding unwanted cells, dead cells, and cell debris from further analysis, is thus a powerful tool for these clinical studies. In this manner, the SMARTer ICELL8 system is an important asset that allows the user to have more control over each experiment and to be more confident in the resulting data."